Drug Type Enzyme |
Synonyms Bi-Sialidase, E 602, E-602 |
Target- |
Mechanism T lymphocytes stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 2 | US | 11 Feb 2022 | |
Bladder Cancer | Phase 2 | US | 11 Feb 2022 | |
Breast Cancer | Phase 2 | US | 11 Feb 2022 | |
Colonic Cancer | Phase 2 | US | 11 Feb 2022 | |
Gastrooesophageal junction cancer | Phase 2 | US | 11 Feb 2022 | |
Head and Neck Neoplasms | Phase 2 | US | 11 Feb 2022 | |
Melanoma | Phase 2 | US | 11 Feb 2022 | |
Non-Small Cell Lung Cancer | Phase 2 | US | 11 Feb 2022 | |
Ovarian Cancer | Phase 2 | US | 11 Feb 2022 | |
Pancreatic Cancer | Phase 2 | US | 11 Feb 2022 |
GLIMMER-01 (AACR2023) Manual | Phase 1/2 | 32 | qhhmfzfdel(fujdnrdnci) = The most frequent adverse event was infusion-related reactions which were primarily grade 1-2 and clinically manageable. kfzczysygb (dckngofrzv ) | Positive | 14 Apr 2023 |